Pharmacological considerations in antiretroviral therapy

Antiviral Therapy

Volumn 3, Issue SUPPL. 4, 1998, Pages 9-12

  Sommadossi, Jean Pierre ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

EID: 0031798147     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337:725-733.
2. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Jsu A, Granneman GT, Ho DD, Boucher CAB, Leonard JM, Norbeck DW & Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766.
3. Department of Health & Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 1998; 47:43-82.
4. Murphy R, Sommadossi P-P, Lamson M, Gagnier P, Hall D, Myers M & Dusek A. Antiviral effect and pharmacokinetic interactions between nevirapine and indinavir in HIV-1 infected individuals. Journal of Infectious Diseases 1998; (in press).
5. Morse GD, Shelton MJ, Hewitt RG, Adams JM, Balswin JP, Della-Coletta AA, Freimuth WW & Cox SR. Ritonavir (RIT) pharmacokinetics (PK) during combination therapy with delavirdine (DLV). 5th Conference on Retroviruses and Opportunistic Infections, 1-5 February 1998, Chicago, III., USA. Abstract 343.
6. Calvez V, Descamps D, Valantin M-A, Cecile A, Damond F, Yuon A, Maatherson S, Bonmarchand M, Coutellier A, Costagliola D, Katlama C & Vezinet FB. Resistance data for stavudine in combination with lamivudine - Altis 1 and 2. Antiviral Therapy 1997; 2 (Supplement 3):107-108.
7. Sommadossi J-P, Zhou XJ, Moore J, Havlir DV, Frieland G, Tierney C, Smeaton L, Fox L, Richman D, & Pollard R. Impairment of stavudine (d4T) phosphorylation in patients receiving a combination of zidovudine (ZDV) and d4T (ACTG 290). 5th Conference on Retroviruses and Opportunistic Infections, 1-5 February 1998, Chicago, III., USA. Abstract 3.